Newborn screening for cystic fibrosis

Area of Science:

• Medical Genetics
• Pediatric Pulmonology
• Public Health Screening

Background:

• Cystic Fibrosis (CF) is a genetic disorder leading to irreversible organ damage.
• Early diagnosis via newborn screening and prompt treatment is hypothesized to improve patient outcomes and quality of life.
• The potential benefits and harms of neonatal screening for CF require rigorous evaluation.

Purpose of the Study:

• To evaluate the evidence for improved survival and reduced long-term morbidity in cystic fibrosis patients diagnosed through neonatal screening.
• To assess the safety and adverse effects associated with current cystic fibrosis screening protocols.
• To determine if early diagnosis and treatment enhance patient outcomes compared to clinical diagnosis.

Main Methods:

• Systematic review of randomized or pseudorandomized controlled trials comparing neonatal screening with early treatment versus clinical diagnosis with later treatment.
• Searched the Cochrane Cystic Fibrosis and Genetic Disorders Trials Register and contacted pharmaceutical companies.
• Independent assessment of trial eligibility, quality, and data extraction by four reviewers.

Main Results:

• Two trials involving over 1.1 million neonates met inclusion criteria; data from only one study was analyzable.
• The analyzable study indicated a reduced risk of low weight and height in screened patients.
• Evidence on adverse effects was inconclusive due to unclear timing of assessments; screening appeared potentially cost-effective but lacked detailed cost-benefit analysis.

Conclusions:

• Limited randomized controlled trials exist for neonatal cystic fibrosis screening effectiveness.
• Current data provides minimal evidence of benefit or harm from neonatal screening for cystic fibrosis.
• Individual patient data from existing studies is needed for a comprehensive meta-analysis and definitive conclusions.